Nynomic

Nynomic AG is a Wedel-based (Schleswig-Holstein, Germany) holding for a group of six specialist photonics and optical-measurement subsidiaries: tec5 (spectroscopy instruments), Image Engineering (camera-quality testing), m-u-t AG (process spectroscopy), LayTec (real-time thin-film monitoring for semiconductor and OLED production), Spectral Engines (handheld NIR sensors, now part of group) and Avantes (fiber-optic spectrometers). Listed in Frankfurt under the M7U ticker since 2007, the group operates on a federated model — each subsidiary keeps its brand, engineering team and direct customer relationships, while Nynomic centralizes procurement, IT and financial reporting.

Trailing twelve-month revenue is 97.7 million EUR, down 11.6 percent year-over-year. The decline is concentrated in two areas: the LayTec semiconductor-equipment business (postponed customer orders from Asian foundry capex resets in 2024) and the m-u-t agricultural-spectroscopy division (delayed European farm-equipment replacement cycle). Gross margin printed at 18.5 percent — unusually low for a precision-instruments business and a function of the temporary revenue compression absorbing fixed manufacturing overhead. Operating margin is minus 4.9 percent, net margin minus 6.8 percent. Free cash flow remained positive at 5.8 million EUR — the structural data point that separates Nynomic from cyclical semiconductor equipment names that turn cash-negative at the trough.

The balance sheet is conservative: 18 million EUR of net debt against 95 million EUR of equity, a 17.7 percent debt-to-equity ratio that reflects the German Mittelstand capital-allocation discipline. The 548-employee group has not cut R&D spending through the down cycle — at roughly 8.5 percent of revenue, R&D continues to fund the LayTec semiconductor-inspection roadmap and the AI-enabled spectroscopy development at tec5.

The shareholder register is the structural feature. The Hägebarth family — descendants of Nynomic founder Dr. Maik Hägebarth — controls roughly 27 percent of the share capital through Hägebarth Beteiligungs GmbH and personal holdings. Lang & Schwarz AG (market-making house) holds 5 percent. The free float is therefore roughly 68 percent of the 6.55 million shares outstanding, but turnover is thin: average daily trading volume of roughly 12,000 shares (250,000 EUR notional) puts this firmly in the German Nebenwert (micro-cap) bracket.

Institutional ownership is concentrated in German specialist-industrial-value mandates: Universal-Investment Mittelstand-Vermögensaufbau-Fonds, Lupus alpha Smaller Companies, and a handful of Hamburg/Schleswig-Holstein family-office mandates. The HSBC Trinkaus Smaller-Caps research desk is the only continuous sell-side coverage; consensus target is 26.00 EUR (34 percent upside) from a two-analyst panel.

Insider buying has been steady through 2025 — executive board chairman Maik Hägebarth reported four open-market purchases between January and April 2025 in the 14-17 EUR range, totaling roughly 480,000 EUR of personal capital deployed. Short interest is zero. There is no smart-money bear thesis on Nynomic — the structural question is whether the LayTec semiconductor-inspection cycle inflects in 2026 and whether the m-u-t agricultural business reaccelerates with the European farm-machinery replacement-cycle resumption.

At 19.35 EUR the market cap is 127 million EUR and trailing revenue is 97.7 million EUR — a price-to-sales ratio of 1.3x. The European photonics-instruments peer set puts Bruker Corporation at 4.5x P/S, HORIBA at 1.6x, Spectris at 2.8x and Vaisala at 4.2x. Even at the lower end of the comp range (1.8x for cyclical small-cap exposure), Nynomic would trade at roughly 27 EUR per share. The sell-side consensus target of 26.00 EUR (34 percent upside) is in line with this frame. The 27.45x forward P/E looks high in isolation, but represents the cyclical-trough earnings number — fiscal 2027 normalized EPS is plausibly 1.30-1.50 EUR, which at the historical 14-16x P/E puts fair value at 19-24 EUR per share. The Free-Cash-Flow yield is the cleaner valuation lens: 5.8 million EUR FCF on 127 million EUR market cap is a 4.6 percent FCF yield even at the cyclical bottom, roughly 8-10 percent at mid-cycle. The bull case for a 30 EUR fair value requires LayTec semiconductor revenue to recover to the 2023 peak by fiscal 2027.

1. July 2026: H1 2026 financial report. The watch items are LayTec order-book trajectory, gross-margin recovery (needs to clear 25 percent to validate cyclical-bottom thesis), and m-u-t agricultural-spectroscopy demand commentary tied to the European farm-equipment replacement cycle.
2. October 2026: Photonics-industry K-Messe and SEMICON Europa conferences. Historical setting for LayTec major customer-win announcements and tec5 new-product launches. Nynomic regularly schedules investor-meeting clusters around these events.
3. Q1 2027: Fiscal year 2026 preliminary results. The first full-year print under a normalized semiconductor-capex environment. If LayTec revenue recovers to 2022-2023 levels and gross margin normalizes above 28 percent, the share price should rerate materially.

Nynomic is a textbook German Mittelstand small-cap setup: family-controlled, federated structure with six specialist subsidiaries, conservative balance sheet, 15-year track record of positive operating cash flow through cycles, and a cyclical-trough valuation that screens cheap on every metric except headline P/E. The 1.3x P/S and 1.35x P/B are the relevant signals — both well below the historical range, both reflecting a temporary revenue compression rather than a structural impairment.

The bull case is straightforward: semiconductor-foundry capex inflects in 2026, LayTec revenue recovers to the 2023 peak by fiscal 2027, group gross margin normalizes back to 30-plus percent, and the share price rerates to the 26-30 EUR consensus range over 18-24 months. The bear case is the LayTec customer concentration risk crystallizes, gross margin stays compressed, and the Frankfurt micro-cap discount keeps the share price range-bound between 18 and 22 EUR. The family-control structure and 4.6 percent FCF yield at the trough provide downside protection that is unusual for a cyclical small-cap.

Position sizing for retail: this is a patient value-investing position, not a cyclical trade. The illiquidity blocks any tactical exit — entry and exit need to be patient. The dividend yield, FCF yield and family-buying signal all support sizing on the higher side for a small-cap allocation. This is a 2-3 year story.